Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $21.00 Consensus Price Target from Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been given a consensus recommendation of “Buy” by the six ratings firms that are currently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $21.00.

A number of research firms recently weighed in on ARTV. Needham & Company LLC reissued a “buy” rating and issued a $23.00 target price on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th. HC Wainwright assumed coverage on shares of Artiva Biotherapeutics in a research report on Monday, December 30th. They set a “buy” rating and a $20.00 target price on the stock.

Artiva Biotherapeutics Stock Up 0.4 %

ARTV opened at $5.40 on Friday. The firm’s 50-day moving average is $9.91. Artiva Biotherapeutics has a 52 week low of $5.30 and a 52 week high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). On average, sell-side analysts forecast that Artiva Biotherapeutics will post -4.95 EPS for the current fiscal year.

Institutional Investors Weigh In On Artiva Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new position in Artiva Biotherapeutics during the 3rd quarter valued at about $42,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Artiva Biotherapeutics during the fourth quarter valued at approximately $52,000. MetLife Investment Management LLC purchased a new stake in shares of Artiva Biotherapeutics in the third quarter worth approximately $135,000. JPMorgan Chase & Co. bought a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $166,000. Finally, Barclays PLC purchased a new position in Artiva Biotherapeutics during the 3rd quarter valued at $304,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.